A Phase I, Open Label, Study of 3,4-Methylenedioxymethamphetamine (MDMA) Tolerability and Pharmacokinetics in Subjects With Moderate Hepatic Impairment Compared to Matched Control Subjects With Normal Hepatic Function

Phase: PHASE1 | Sponsor: Lykos Therapeutics | Compound: MDMA

Status

planned

Institution

Lykos Therapeutics

Start date

2026-03-29

End date

2028-12-01

Registry ID

NCT03606538

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.